Ana Belén
Herrero Hernández
Dana–Farber Cancer Institute
Boston, Estados UnidosDana–Farber Cancer Institute-ko ikertzaileekin lankidetzan egindako argitalpenak (1)
2020
-
CRISPR/Cas9-generated models uncover therapeutic vulnerabilities of del(11q) CLL cells to dual BCR and PARP inhibition
Leukemia, Vol. 34, Núm. 6, pp. 1599-1612